Mainz Biomed Shareholders Approve All Proposals at AGM
Ticker: MYNZ · Form: 6-K · Filed: May 31, 2024 · CIK: 1874252
| Field | Detail |
|---|---|
| Company | Mainz Biomed N.V. (MYNZ) |
| Form Type | 6-K |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agm, shareholder-meeting, corporate-governance
TL;DR
Mainz Biomed AGM: All proposals passed, management has shareholder backing.
AI Summary
Mainz Biomed N.V. held its annual general meeting of ordinary shareholders on May 31, 2024, in Amsterdam, The Netherlands. A quorum was present, and all proposals submitted to the shareholders were approved. The company attached a press release detailing the meeting and other matters to its Form 6-K filing.
Why It Matters
Shareholder approval of all proposals at the annual general meeting indicates management's alignment with shareholder interests and smooth operational progress.
Risk Assessment
Risk Level: low — The filing is a routine report of an annual general meeting where all proposals were approved, indicating no immediate negative surprises.
Key Players & Entities
- MAINZ BIOMED N.V. (company) — Filer of the report
- May 31, 2024 (date) — Date of the annual general meeting
- Amsterdam, The Netherlands (location) — Location of the annual general meeting
FAQ
What was the purpose of the Form 6-K filing?
The Form 6-K filing was made to report on the annual general meeting of Mainz Biomed N.V.'s ordinary shareholders held on May 31, 2024, and to attach a press release discussing the meeting and other matters.
When and where was the annual general meeting held?
The annual general meeting was held on May 31, 2024, in Amsterdam, The Netherlands.
Was a quorum present at the annual general meeting?
Yes, a quorum was present for the annual general meeting.
Were all proposals approved at the meeting?
Yes, all proposals brought before the holders of ordinary shares at the meeting were approved.
What is attached as Exhibit 99.1 to this filing?
Exhibit 99.1 is a press release discussing the annual general meeting and other matters.
Filing Stats: 255 words · 1 min read · ~1 pages · Grade level 9.4 · Accepted 2024-05-31 17:01:03
Filing Documents
- ea0207187-6k_mainzbio.htm (6-K) — 11KB
- ea020718701ex99-1_mainzbio.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-24-048526.txt ( ) — 38KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant’s name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Other Events On May 31, 2024, we held the annual general meeting of our holders of ordinary shares in Amsterdam, The Netherlands. A quorum was present for such meeting, and all proposals brought before the holders of our ordinary shares at such meeting were approved. Attached as Exhibit 99.1 hereto is a press release discussing such annual general meeting and other matters. This current report on Form 6-K and the exhibit hereto are hereby incorporated by reference into our registration statement on Form F-3 (no. 333-269091) as well as our registration statement on Form S-8 (no. 333-273203). Exhibit No. Exhibit 99.1 Press release, dated May 31, 2024, entitled “Mainz Biomed Reports Results of 2024 Annual General Meeting” 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 31, 2024 By: /s/ William J. Caragol William J. Caragol Title: Chief Financial Officer 2